Thyroid Diseases: Clinical Trials

72 trials for Thyroid Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

72 completed. 72 Phase 1, 23 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 172Completed 72
Phase 223Completed 23

Follow Thyroid Diseases: new trials by email Literature Review of Thyroid Diseases trials Research Report on Thyroid Diseases

Trials (filtered) newest first · largest first

All 72 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effects of Different Administration Routes of Dexmedetomidine on Postoperative Sleep Quality in Patients Undergoing Thyroidectomy
Dexmedetomidine (DEX), Saline - Thyroid Diseases
Phase 1 / Phase 2CompletedThe Second People's Hospital of Huai'an1202026-01-052026-09-11
A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants
Teprotumumab, Placebo - Healthy Volunteers
Phase 1CompletedAmgen202025-08-262026-02-27
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
ARV-806 - KRAS G12D Mutation, Advanced Solid Cancer
Phase 1 / Phase 2CompletedArvinas Inc.762025-05-292026-11-17
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor
Phase 1 / Phase 2CompletedSensei Biotherapeutics, Inc.982023-05-312026-09-02
Prospective Comparison of the Effect on Antiadhesive Barriers During Thyroid Surgery
Oxidized regenerated cellulose(ORC), Hyaluronic acid(HA) - Thyroidectomy, Goiter
Phase 1CompletedNational Taiwan University Hospital452023-05-242025-09-19
Study of ZB001 in Chinese Patients With Thyroid Eye Disease
ZB001 for injection - Thyroid Eye Disease
Phase 1CompletedZenas BioPharma (USA), LLC172023-05-102025-04-11
A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants
Teprotumumab - Healthy Volunteers
Phase 1CompletedAmgen442023-03-242024-11-05
A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion - Cancer, Solid Tumor
Phase 1 / Phase 2CompletedKineta Inc.402023-03-032026-10-05
Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)
lonigutamab, Placebo - Thyroid Eye Disease
Phase 1 / Phase 2CompletedACELYRIN Inc.312023-02-142025-07-01
Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor
CNSI-Fe(II) 30 mg, CNSI-Fe(II) 60 mg, CNSI-Fe(II) 90 mg - Advanced Solid Tumor, Lung Cancer
Phase 1CompletedSichuan Enray Pharmaceutical Sciences Company192022-11-172025-08-03
A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease
Teprotumumab - Thyroid Eye Disease
Phase 1CompletedAmgen162022-07-142024-06-21
Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer
177Lu-DOTA-EB-FAPI 1 radionuclide therapy, 177Lu-DOTA-EB-FAPI 2 radionuclide therapy, 177Lu-DOTA-EB-FAPI 3 radionuclide therapy - Refractory Thyroid Gland Carcinoma, Refractory Thyroid Gland Papillary Carcinoma
Phase 1CompletedThe First Affiliated Hospital of Xiamen University122022-06-152025-04-01
A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease
LASN01, Placebo - Pulmonary Fibrosis, Thyroid Eye Disease
Phase 1 / Phase 2CompletedLassen Therapeutics 1 PTY LTD752022-06-062024-12-30
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel - Advanced Solid Tumor, Cholangiocarcinoma
Phase 1 / Phase 2CompletedTransThera Sciences (Nanjing), Inc.842022-04-132025-06-12
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
LOXO-260 - Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
Phase 1CompletedEli Lilly and Company702022-03-232026-08-21
Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW
Bevacizumab-IRDye800CW - Thyroid Carcinoma, Surgery
Phase 1CompletedUniversity Medical Center Groningen202021-11-292024-08-22
Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer
Targeted alpha therapy - Thyroid Cancer
Phase 1CompletedOsaka University112021-11-202025-04-24
Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult Subjects
MYMD-1, Placebo - Hashimoto Disease
Phase 1CompletedTNF Pharmaceuticals, Inc.322021-04-262023-03-27
A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
CM-24 and Nivolumab - Dose Escalation, CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion - Solid Tumor, Non Small Cell Lung Cancer
Phase 1 / Phase 2CompletedFamewave Ltd.792021-03-192024-12-27
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TT-00420, Nab-Paclitaxel - Advanced Solid Tumor, Cholangiocarcinoma
Phase 1 / Phase 2CompletedTransThera Sciences (Nanjing), Inc.2032021-03-142024-04-26

Showing 20 of 72. Sign in to see all of them.

Narrower conditions

Thyroid Neoplasms (43)  ·  Thyroid Cancer, Papillary (16)  ·  Breast Neoplasms (15)  ·  Carcinoma, Non-Small-Cell Lung (14)  ·  Head and Neck Neoplasms (14)  ·  Melanoma (14)  ·  Ovarian Neoplasms (14)  ·  Prostatic Neoplasms (14)  ·  Pancreatic Neoplasms (13)  ·  Adenocarcinoma, Follicular (11)  ·  Colonic Neoplasms (11)  ·  Colorectal Neoplasms (11)  ·  Lung Neoplasms (11)  ·  Sarcoma (11)  ·  Urinary Bladder Neoplasms (11)

Broader conditions

Endocrine System Diseases (70)  ·  Neoplasms by Site (49)  ·  Endocrine Gland Neoplasms (48)  ·  Neoplasms (41)  ·  Head and Neck Neoplasms (36)  ·  Neoplasms by Histologic Type (36)  ·  Neoplasms, Glandular and Epithelial (33)  ·  Carcinoma (31)  ·  Adenocarcinoma (27)  ·  Skin Diseases (24)  ·  Skin and Connective Tissue Diseases (24)  ·  Female Urogenital Diseases (22)  ·  Female Urogenital Diseases and Pregnancy Complications (22)  ·  Lung Diseases (22)

Interventions

teprotumumab (4)  ·  Iodine-131 (3)  ·  Triiodothyronine (3)  ·  Azacitidine (2)  ·  Injections (2)  ·  Methimazole (2)  ·  Paclitaxel (2)  ·  Rituximab (2)  ·  Thyrotropin Alfa (2)  ·  Trastuzumab (2)  ·  Vemurafenib (2)  ·  belinostat (2)  ·  pazopanib (2)  ·  1-phenyl-3,3-dimethyltriazene (1)  ·  130-nm albumin-bound paclitaxel (1)

Sponsors

National Cancer Institute (NCI) (5)  ·  Amgen (4)  ·  Exelixis (3)  ·  Memorial Sloan Kettering Cancer Center (3)  ·  European Organisation for Research and Treatment of Cancer - EORTC (2)  ·  TNF Pharmaceuticals, Inc. (2)  ·  TransThera Sciences (Nanjing), Inc. (2)  ·  University Medical Center Groningen (2)  ·  University of Pennsylvania (2)  ·  Valerio Therapeutics (2)  ·  ACELYRIN Inc. (1)  ·  AHS Cancer Control Alberta (1)  ·  AV7 Limited (1)  ·  Alume Biosciences, Inc. (1)  ·  Apitope International NV (1)

Countries

United States (47)  ·  China (10)  ·  Netherlands (5)  ·  United Kingdom (5)  ·  Canada (4)  ·  Denmark (3)  ·  France (3)  ·  Germany (3)  ·  Spain (3)  ·  Australia (2)  ·  Belgium (2)  ·  Hong Kong (2)  ·  South Korea (2)  ·  Taiwan (2)  ·  Egypt (1)

Top investigators

Anne R Cappola, MD,ScM (2)  ·  Alan L Ho, MD, PhD (1)  ·  Alexander McEwan, MB, FCRPC (1)  ·  Anthony W. Tolcher, MD (1)  ·  Art Simon, PhD (1)  ·  Chih-Yi Liao (1)  ·  Christopher R McHenry, MD (1)  ·  Cornelis J. A. Punt, MD, PhD (1)  ·  Dan Liang, MD (1)  ·  Daniel El-Fassi, MD (1)  ·  Dave Singh, Professor (1)  ·  Du Lam, MD (1)  ·  Edward S. Kim, MD (1)

Results publications

PMID 17985341, PMID 19192962, PMID 19372041, PMID 19602035, PMID 19735988, PMID 19850691, PMID 20145168, PMID 21367608, PMID 21606412, PMID 22219499, PMID 23489023, PMID 23676418, PMID 23868427, PMID 24827131, PMID 26221138, PMID 27240885, PMID 28662033, PMID 28744123, PMID 29186019, PMID 30184767, PMID 32416981, PMID 32510916, PMID 34118197, PMID 34118198, PMID 34766118, PMID 35045748, PMID 35389070, PMID 35715405, PMID 35962206, PMID 37171634, PMID 37282666, PMID 37916501, PMID 37934000, PMID 38009200, PMID 38017325, PMID 39863139, PMID 40595556, PMID 40613790, PMID 40639400, PMID 41886723, PMID 42249319, PMID 42816483

NIH funding

2016 (2), R61HL146390 (2), N01CM00032 (1), N01CM00038 (1), N01CM00071 (1), N01CM00099 (1), N01CM00100 (1), N01CM62201 (1), P30CA014599 (1), P30CA015704 (1), P30CA043703 (1), P30CA072720 (1), U01CA062502 (1), U01CA062505 (1), U01CA069912 (1)